Navigation Links
It's a knock out: eIF4E-specific anti-sense oligonucleotides knock down cancer
Date:9/4/2007

A new study by Jeremy Graff and colleagues from Eli Lilly and Company has demonstrated the anti-cancer effect of a new therapeutic in a mouse model of human tumors and has spawned clinical trials to test the ability of this therapeutic to treat human cancers. As highlighted in the accompanying commentary by Celeste Simon and colleagues from the University of Pennsylvania, Philadelphia, if the therapeutic is as effective in clinical trials as it was in mice it will be useful for the treatment of a broad range of cancers.

The growth of many tumors is promoted by increased expression of the protein eIF4E, but no eIF4E-specific therapy has yet been developed. In this study, the intravenous administration of eIF4E-specific antisense oligonucleotides (ASOs) to mice bearing human tumors substantially inhibited tumor growth. Importantly, although these ASOs also decreased eIF4E expression in normal tissues, the function of the normal tissues analyzed was not compromised. The authors therefore suggest that tumor cells are more susceptible to decreased expression of eIF4E than normal cells, meaning that eIF4E-specific ASOs should not cause damage to normal tissues.

TITLE: Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity

AUTHOR CONTACT:

Jeremy R. Graff
Eli Lilly and Company, Indianapolis, Indiana, USA.
Phone: (317) 277-0220; Fax: (317) 277-3652; E-mail: graff_jeremy@lilly.com.

View the PDF of this article at: https://www.the-jci.org/article.php?id=32044

ACCOMPANYING COMMENTARY:

TITLE: Taking aim at translation for tumor therapy

AUTHOR CONTACT:

M. Celeste Simon
Abramson Family Cancer Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Phone: (215) 746-5532; Fax: (215
'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Alcohol a potential carcinogen: knocking on the door: pay heed!
2. Knock on the Head – No Small Thing After Al
3. Lethal Hospital Bug Tough to Knock Down, Statistics Reveal
4. The Tech Savvy Patient Knocks on the Doors of Telemedicine and Virtual Clinics
5. Knocking Out Survival Protein Could Aid Leukemia Treatment
6. Knocking Out Survival Protein Could Fight Leukemia
7. Chilean Presidents Cousin Successfully Tests Allergy Knockout Technique on Mice
8. Anti-Sense Drugs and Nanotechnology Offer New Hope In Cancer Fight
9. Fibroids unlikely to Turn Cancerous
10. Virus Level could Predict Cervical Cancer Risk
11. Cancer Doctors Okays Controversial Prostate Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the global ... grow to $15.2 billion by 2019, with a ... Increasing industrialization is driving significant growth across ... range of industrial applications such as military and ...
(Date:8/20/2014)... San Mateo, CA (PRWEB) August 20, 2014 ... their newest product—the Really Little Green Pouch —to ... easier to feed babies and toddlers homemade foods. ... says Little Green Pouch co-founder Maggie Crawford. She ... their kids, to limit exposure to things like pesticides ...
(Date:8/20/2014)... 2014 "I decided that there needed ... an optimal manner without the hassles associated with using ... , The patent-pending DR. GATES ORAL-HYGIENE TOOL provides an ... It promotes good oral hygiene and fresh breath, and ... Convenient, compact, affordable, eco-friendly and easy to use, the ...
(Date:8/20/2014)... been chosen by Plymouth University to be an official ... 2009 to raise awareness of, and funding for, scientific ... tumour patients. , A range of events and activities ... charity, and members of staff and students, as well ... fundraise and volunteer. The involvement of the wider community ...
(Date:8/20/2014)... Fresh from the cradle of a world-class running city, an ... , Urbini, a new collection of versatile baby gear from ... jogger to its lineup. , The Avi has been in ... the latest racing styles and a set of features to ... a swift, smooth ride on runs, power-walks and causal strolls. ...
Breaking Medicine News(10 mins):Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:Little Green Pouch Launches New Product to Help Health-conscious Parents Reduce Babies’ Eco-footprint 2Health News:Plymouth University chooses Brain Tumour Research as official charity 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2
... available since the middle of 2011 as a treatment ... early benefit assessment pursuant to the "Act on the ... German Institute for Quality and Efficiency in Health Care ... added benefit in comparison with the previous standard therapy. ...
... study, initiated by the Swiss researchers and published in ... in the brain. Anxiety disorders constitute a complex ... Patients suffering from such disorders fear certain situations or ... the real danger they present. The amygdala, a ...
... -- The presence of circulating tumor cells in the blood ... have just been diagnosed with inflammatory breast cancer, according to ... research shows that these stray tumor cells may signal that ... even before imaging reveals any metastases. The results will ...
... Kathleen Doheny HealthDay Reporter , THURSDAY, Dec. ... especially starches, may boost the risk of breast cancer ... public health doctoral student at the University of California, ... carbohydrates, particularly starchy foods such as potatoes, that breast ...
... Biology (FASEB) is pleased to announce the addition of ... the Society for Pediatric Research, which will bring the ... very dynamic groups representing extremely important areas of research, ... said FASEB President Joseph C. LaManna, PhD. "We welcome ...
... a University of Notre Dame researcher, is one of the coauthors ... scientists in academia and industry that calls for strong steps to ... bacteria. The group issued a priority list of steps that need ... The paper is an outgrowth of a meeting the group ...
Cached Medicine News:Health News:Boceprevir: Indication of added benefit for specific patients 2Health News:Boceprevir: Indication of added benefit for specific patients 3Health News:The cortex plays an essential part in emotional learning 2Health News:Circulating tumor cells not linked to survival in newly diagnosed inflammatory breast cancer 2Health News:Circulating tumor cells not linked to survival in newly diagnosed inflammatory breast cancer 3Health News:Starchy Foods May Boost Risk of Breast Cancer Recurrence 2Health News:Starchy Foods May Boost Risk of Breast Cancer Recurrence 3Health News:New paper calls for strong steps to tackle antibiotic resistance 2
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets ... Drugs - Global Strategic Business Report" report to their ... for Human Growth Hormone Drugs in US$ Million by the ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ...
(Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim ... Administration (FDA) accepted for review the New Drug ... tiotropium and olodaterol delivered via the Respimat ® ... once-daily maintenance treatment of airflow obstruction in patients ... bronchitis and/or emphysema. Tiotropium + olodaterol FDC will ...
(Date:8/19/2014)... Aug. 19, 2014  Stryker Corporation,s Orthopaedics Division, the Official ... is bringing its message of joint health to golf fans ... this week at The Barclays.  The company,s fan destination ... Spectator Village near the 17 th fairway at the ... on Thursday, August 21 st .    At ...
Breaking Medicine Technology:Global Human Growth Hormone Drugs - Strategic Business Report 2014 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 2Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 3Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 4Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 5
... 31, 2011 Boston Scientific Corporation (NYSE: ... Food and Drug Administration (FDA) has approved its ... and delivery of diagnostic, embolic and therapeutic materials ... be used by interventional radiologists for minimally invasive ...
... Endologix, Inc. (Nasdaq: ELGX ), ... announced today the publication of favorable clinical results ... of abdominal aortic aneurysm (EVAR).  The peer-reviewed article ... trial, with successful aneurysm exclusion in all patients, ...
Cached Medicine Technology:Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System 2Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System 3Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System 4Endologix Announces Favorable Clinical Results for Nellix Technology 2Endologix Announces Favorable Clinical Results for Nellix Technology 3
... multifunction plate reader that offers four different ... time-resolved fluorescence, high-perfomance luminescence and absorbance. The ... that deliver reagent at the point of ... can be performed easily and allowing the ...
This new dedicated VICTOR2 model is for fluorescence and luminescence measurements....
... VICTOR2 multilabel counter with ... stacker and robot loading ... density time-resolved fluorescence, luminescence ... of the instrument is ...
This is the modular manually operated VICTOR2 multilabel counter, with the addition of a xenon flash lamp for time-resolved fluorescence counting. Along with this option comes flash absorbance and du...
Medicine Products: